Platelet Reactivity Clinical Trial
Official title:
Ticagrelor in Comparison to Prasugrel for Early Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)
This is a single-center, randomized, single-blind, investigator-initiated, pharmacodynamic
study with a parallel design. Patients with ST elevation myocardial infarction, undergoing
primary percutaneous coronary intervention will be randomized after informed consent, in a
1:1 ratio to the following treatment groups:
Group Α: Ticagrelor 180mg loading dose (LD), followed by a 90mg x2 maintenance dose
(MD)starting 12±6 hours post LD, until Day 5 (5 days after randomization) Group Β: Prasugrel
60 mg LD followed by 10mg x1 MD starting 24 hours post LD, until Day 5 (5 days after
randomization).
Platelet reactivity assessment will be performed at randomization (Hour 0) and at 1, 2, 6,
24 hours after randomization, and on Day 5. Documentation of major adverse cardiac events
(death, myocardial infarction, stroke, revascularization procedure with PCI or CABG)and
serious adverse events (bleeding, other adverse events)will be performed until Day 5.
n/a
Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT02808039 -
Is There a Transient Rebound Effect of Platelet Reactivity Following Cessation of Dual Antiplatelet Therapy With Ticagrelor - a Single Center Prospective Observational Trial
|
N/A | |
| Completed |
NCT01961856 -
Ticagrelor Loading Dose Versus Clopidogrel Loading and Reloading With Ticagrelor.
|
Phase 3 | |
| Recruiting |
NCT03525145 -
Platelet Reactivity And Clinical ThrombotIC Events Study
|
||
| Completed |
NCT01463150 -
Prasugrel 5mg Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Aged ≥75 Years and/or Weighing <60 kg Post Percutaneous Coronary Intervention (PCI)
|
Phase 4 | |
| Recruiting |
NCT03614832 -
Ticagrelor and Clopidogrel on Platelet Aggregation in Clopidogrel Resistance's Patients With CHD
|
Phase 4 | |
| Completed |
NCT01835353 -
High (100mg) Versus Standard (60mg) Loading Dose of Prasugrel in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)
|
Phase 3 | |
| Completed |
NCT04001894 -
Ticagrelor and Clopidogrel on Platelet Effects in Chinese Patients With Stable Coronary Artery Disease
|
Phase 4 | |
| Recruiting |
NCT05773989 -
Pharmacodynamic Outcomes in CCS Patients Treated With an Individualized Treatment Strategy
|
Phase 4 | |
| Completed |
NCT01511471 -
Ticagrelor in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis
|
Phase 3 | |
| Completed |
NCT00827346 -
Platelet Function Monitoring in Patients Treated With Clopidogrel at the Time of Primary Percutaneous Coronary Angioplasty
|
Phase 2/Phase 3 | |
| Completed |
NCT00976196 -
Platelet Hyperreactivity Project
|
N/A | |
| Recruiting |
NCT05367336 -
Platelet Reactivity With Fentanyl, Morphine, or no Narcotic
|
Early Phase 1 | |
| Completed |
NCT03679091 -
Low-dose of Ticagrelor and Standard-dose Clopidogrel on Platelet Effects in Chinese Patients With Stable CAD.
|
Phase 4 | |
| Recruiting |
NCT05657041 -
Body Weight Adjusted Clopidogrel Treatment in Patients With CORonary Artery Disease
|
Phase 2/Phase 3 |